PN6047 and respiratory depression
Since 2008 PharmNovo has developed novel molecules which are highly selective, potent and effective in animal models of chronic pain. We have designed compounds with ligand bias which means that they have a very favourable activity profile with none of the unwanted effects characteristic of conventional opioids that act mainly through mu opioid receptors. Our compounds are agonists of the delta opioid receptor, activation of which is known to effectively combat chronic but not acute pain.
Studies with our candidate compound, PN6047, have revealed no unwanted behavioural, cardiovascular or gastrointestinal effects and recently we have demonstrated that PN6047 does not depress respiration which is a potentially fatal side effect of conventional opioids. We believe that PN6047 could contribute significantly in the worldwide battle against conventional opioid addiction and toxicity.
PN6047 and respiratory depression
Since 2008 PharmNovo has developed novel molecules which are highly selective, potent and effective in animal models of chronic pain. We have designed compounds with ligand bias which means that they have a very favourable activity profile with none of the unwanted effects characteristic of conventional opioids that act mainly through mu opioid receptors. Our compounds are agonists of the delta opioid receptor, activation of which is known to effectively combat chronic but not acute pain.
Studies with our candidate compound, PN6047, have revealed no unwanted behavioural, cardiovascular or gastrointestinal effects and recently we have demonstrated that PN6047 does not depress respiration which is a potentially fatal side effect of conventional opioids. We believe that PN6047 could contribute significantly in the worldwide battle against conventional opioid addiction and toxicity.
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more